Generating hair follicles through electrical stimulation
Jan 17 2022
The team from the local Translational Research Initiative for Cellular Engineering and Printing (TRICEP) has launched its new 3D bioprinting system on the global stage.
3DREDI is a 3D bioprinting system designed to equip users with the essential hardware and skills to embark on projects in the rapidly emerging bioprinting industry. The system was designed and manufactured in Wollongong, NSW, and the online launch attracted interest from countries including India, USA, Indonesia, Finland and Dubai.
3DREDI features an intuitive bioprinting platform, and performs as both a research and education tool. The system also comes complete with interactive printing and characterisation tutorials to allow educators and students to familiarise themselves with the capabilities of multi-material bioprinting. Users also receive example cases they can utilise to get started on their own research.
TRICEP Director Prof Gordon Wallace said the realisation of the 3DREDI system is an exciting advance in establishing a new, innovative and sustainable 3D bioprinting industry in the Illawarra.
“Our team is at the forefront of building new approaches to 3D printing, and the success of this project draws on the significant developments we have achieved in this space in recent years and our focus on building our local capabilities in this area,” Gordon said.
“The 3DREDI system is an exciting advance in 3D bioprinting, and the intuitive and flexible platform has been developed with the input of world-leading clinicians.
“3DREDI aims to educate the next generation of biofabricators by equipping them with the skills and tools to tackle big medical challenges, as well as serving as a biomaterials research tool.
TRICEP is a 100 per cent owned initiative of the University of Wollongong (UOW). With the help of the ARC Centre of Excellence for Electromaterials Science (ACES) and the Australian National Fabrication Facility (ANFF) partnership, TRICEP (launched in 2018) has been working to develop and commercialise 3D bioprinting technologies for use in the medical industry to combat significant clinical challenges.
The first 3DREDI will be available for purchase in the first quarter of 2021.